Caplin Point Laboratories Ltd.
Research Caplin Point Laboratories Ltd. (CAPLIPOINT.NS) on Bullrun: market cap INR 174.93B, P/E 26.4, dividend yield 0.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCAPLIPOINT.NS
- ExchangeNSE
- CountryIndia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyINR
- Market capINR 174.93B
- P/E26.4
- Dividend yield0.4%
- Financial periodQ2 2026
- RevenueINR 6.10B
- Net incomeINR 1.77B
- Gross margin59.8%
Valuation Snapshot
latest market cap is INR 174.93B; P/E is 26.4; dividend yield is 0.4%.
Peer valuation comparison
Latest P/E is 26.37x versus a Healthcare sector median of 21.74x (21.3% above).
Latest dividend yield is 0.35% versus a Healthcare sector median of 2.4% (85.4% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | INR 174.93B | 26.4 | 0.4% | 8 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 8 INR, yield 0.4%.
About Caplin Point Laboratories Ltd.
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel, capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag, inhalers, and sprays and IV infusion.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Caplin Point Laboratories Ltd.'s market cap?
Caplin Point Laboratories Ltd.'s market capitalization is INR 174.93B.
What is Caplin Point Laboratories Ltd.'s P/E ratio?
Caplin Point Laboratories Ltd.'s price-to-earnings (P/E) ratio is 26.4.
Does Caplin Point Laboratories Ltd. pay a dividend?
Caplin Point Laboratories Ltd. has a dividend yield of 0.4%.
What does Caplin Point Laboratories Ltd. do?
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel, capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, ophthalmic droppers, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags.